Lymphomas (other / non-specified)

Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

Type: A piolt study of CHOP plus CAMPATH for the primary treatment of ALK-VE peripheral T-Cell Lymphoma.
Eligibility: Diagnosis of Peripheral T cell lymphoma (central review prior to Campath) PTCL not otherwise specified (NOS) AITL-angioimmunoblastic T cell lymphoma  ALK negative anaplastic large cell lymphoma Intestinal T cell lymphoma Aged 18 years or older Bulky stage IA and stages IB-IV (Ann staging system) WHO performance status < 2 Measurable or evaluable disease Written informed consent obtained
Study details: To investigate the feasibility of adding Campath to standard CHOP in the primary chemotherapy treatment of PTCL. To assess the side effect profile and late toxicities of this combination ina standard dose escalation design and to establish an appropriate dose level to inform future studies.